[The identification of minimal residual disease in the bone marrow and peripheral blood in neuroblastoma. The prognostic and therapeutic implications].
Lawrence Faulkner(Faulkner University), Bruno De Bernardi(Istituto Giannina Gaslini), Maria Valeria Corrias(Boston Children's Hospital), Antonino De Paoli(Centro di Riferimento Oncologico), Claudia Milanaccio(Istituto Giannina Gaslini), Daniela Medicina, Veronica Tintori, Alberto Garaventa(Istituto Giannina Gaslini), Paola Scaruffi(Azienda Ospedaliera S.Maria), Elisabetta Viscardi(Azienda Ospedale - Università Padova), Gabriella Bernini(University of Florence), M. S. Lo Piccolo(Palmetto Hematology Oncology), Massimo Brisigotti, Annalisa Tondo, Anna Tamburini, Cristina Rosanda(Palmetto Hematology Oncology)
PubMed
October 19, 1998
Cited by 1
Related Papers
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
|Journal of Clinical Oncology|1993|2.3k
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.
|Journal of Clinical Oncology|1988|608
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2020|482